1-9 of 9
Suresh Agarwal
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE ® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Marion Subklewe, MD, Anthony Stein, MD, Roland B. Walter, MD PhD MS, Ravi Bhatia, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, David Ritchie, MD PhD, Veit Bücklein, MD, Pankit Vachhani, MD, Tian Dai, PhD, Antreas Hindoyan, PhD, Suresh Agarwal, PhD, Abraham Anderson, Sophia Khaldoyanidi, MD PhD, Farhad Ravandi, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 833.
https://doi.org/10.1182/blood-2019-127977
Published: 2019
Journal Articles

Exposure-Response Analysis of Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

Suresh Agarwal, PhD, Sathej Gopalakrishnan, PhD, Sven Mensing, PhD, Jalaja Potluri, MD, John Hayslip, Anna Friedel, Rajeev Menon, PhD, Ahmed Hamed Salem, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5239.
https://doi.org/10.1182/blood-2018-99-116790
Published: 2018
Journal Articles

Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy

Clinical Trials & Observations
Steven Coutre, Michael Choi, Richard R. Furman, Herbert Eradat, Leonard Heffner, Jeffrey A. Jones, Brenda Chyla, Lang Zhou, Suresh Agarwal, Tina Waskiewicz, Maria Verdugo, Rod A. Humerickhouse, Jalaja Potluri, William G. Wierda, Matthew S. Davids
Journal: Blood
Blood (2018) 131 (15): 1704–1711.
https://doi.org/10.1182/blood-2017-06-788133
Published: 2018
Includes: Supplemental data
Journal Articles

Phase 1/2 Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Venetoclax in Japanese Subjects with Chronic Lymphocytic Leukemia

Kiyohiko Hatake, MD PhD, Kazuhito Yamamoto, MDPhD, Noriko Fukuhara, MD PhD, Shigeru Kusumoto, MD, Koji Izutsu, MD, PhD, Ilseung Choi, MD, Hirokazu Nagai, MD PhD, Hideyuki Honda, BS, Junjiro Saeki, MS, Andrew W. Roberts, MS, Paulo Maciag, MD PhD, Suresh Agarwal, MS, PhD RPh, Ahmed Hamed Salem, PhD, Kevin J. Freise, PhD, Tsukasa Kiriyama, PharmD, BSc, Kensei Tobinai, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5352.
https://doi.org/10.1182/blood.V130.Suppl_1.5352.5352
Published: 2017
Journal Articles

Do Statins Enhance the Anti-Cancer Activity of Venetoclax?

Andrew W. Roberts, MS, Tu Xu, PhD, Jia Jia, PhD MBA, Suresh Agarwal, MS, PhD RPh, Ahmed Hamed Salem, PhD, Richard J. Bellin, MS, Lloyd T. Lam, PhD, Joel D. Leverson, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1737.
https://doi.org/10.1182/blood.V130.Suppl_1.1737.1737
Published: 2017
Journal Articles

Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia

Andrew Wei, Stephen A. Strickland, Gail J. Roboz, Jing-Zhou Hou, Walter Fiedler, MD, Tara L. Lin, Giovanni Martinelli, Roland B. Walter, MD PhD, Anoop Enjeti, Kaffa Fakouhi, David E. Darden, Martin Dunbar, Ming Zhu, Suresh Agarwal, Ahmed H. Salem, Mack Mabry, John Hayslip
Journal: Blood
Blood (2016) 128 (22): 102.
https://doi.org/10.1182/blood.V128.22.102.102
Published: 2016
Journal Articles

Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study

Shaji Kumar, MD, Ravi Vij, MD, Jonathan L. Kaufman, MD, Joseph Mikhael, MD, Thierry Facon, MD, Brigitte Pegourie, MD, Lofti Benboubker, Cristina Gasparetto, MD, Martine Amiot, Philippe Moreau, Stefanie Alzate, Jeremy Ross, Martin Dunbar, Tu Xu, Suresh Agarwal, Joel Leverson, Paulo Maciag, Maria Verdugo, Cyrille Touzeau
Journal: Blood
Blood (2016) 128 (22): 488.
https://doi.org/10.1182/blood.V128.22.488.488
Published: 2016
Journal Articles

A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy

Courtney DiNardo, MD, Daniel Pollyea, MD MS, Keith Pratz, MD, Michael J. Thirman, MD, Anthony Letai, MD PhD, Mark Frattini, MD PhD, Brian Jonas, MDPhD, Joel Leverson, PhD, Ming Zhu, PhD, Martin Dunbar, DrPH, Nancy Falotico, Rachel Kirby, BA, Suresh Agarwal, PhD, Mack Mabry, MD, Jalaja Potluri, MD, Rod A. Humerickhouse, MD PhD, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2015) 126 (23): 327.
https://doi.org/10.1182/blood.V126.23.327.327
Published: 2015
Journal Articles

Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results

Shaji K. Kumar, MD, Ravi Vij, MD MBA, Jonathan L. Kaufman, MD, Joseph R. Mikhael, MD, Thierry Facon, MD, Brigitte Pegourie, MD, Lotfi Benboubker, MDPhD, Philippe Moreau, MD, Martine Amiot, PhD, Stefanie Alzate, MS, Lura Morris, BA, Jeremy Ross, PhD, Martin Dunbar, DrPH, Ming Zhu, PhD, Paulo Maciag, MD, Suresh Agarwal, PhD, Joel Leverson, PhD, Sari Heitner Enschede, MD, Rod A. Humerickhouse, MD PhD, Cyrille Touzeau, MD
Journal: Blood
Blood (2015) 126 (23): 4219.
https://doi.org/10.1182/blood.V126.23.4219.4219
Published: 2015